Celularity Inc.

AI-generated fair value estimate for this company.

Method: EV/Revenue multiple with net-debt adjustment: 1.0x TTM revenue multiple applied to $26.55M TTM revenue (typical low multiple for a loss-making, low-growth specialty biologics/commercial-stage cell-therapy company) giving $26.55M enterprise value; less $74.71M total debt plus $6.18M cash (net debt $68.54M); 28.95M shares outstanding (post 1-for-10 reverse split).

Reasoning: Celularity carries heavy debt relative to its commercial revenue base and continues to post large GAAP losses (~$91.8M TTM) so a revenue-multiple-less-net-debt approach is more defensible than a DCF of deeply negative free cash flow; the calculation implies equity value is wiped out by leverage so I floor the per-share estimate at a small positive figure reflecting residual option value in the commercial biologics business and potential refinancing.